BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33293356)

  • 1. Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.
    Tiraboschi C; Gentilini L; Velazquez C; Corapi E; Jaworski FM; Garcia Garcia JD; Rondón Y; Chauchereau A; Laderach DJ; Compagno D
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33293356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity.
    Corapi E; Carrizo G; Compagno D; Laderach D
    Front Immunol; 2018; 9():2190. PubMed ID: 30319642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
    Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
    Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M
    Front Immunol; 2020; 11():1820. PubMed ID: 33013832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
    Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
    Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.
    Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL
    Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
    Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
    Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
    Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
    Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.
    Wang Y; Nangia-Makker P; Balan V; Hogan V; Raz A
    Cell Death Dis; 2010 Nov; 1(11):e101. PubMed ID: 21368866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and immunotherapy combination in advanced prostate cancer.
    Slovin S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.